Navigation Links
Cell Therapeutics Amends 'Modified Dutch Auction' Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes
Date:5/18/2009

SEATTLE, May 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (the "Company" or "CTI") (Nasdaq and MTA: CTIC) today announced that it has amended its "Modified Dutch Auction" tender offer (the "Exchange Offer") to increase the total consideration of its offer to exchange shares of its common stock, no par value (the "Common Stock"), and cash for an aggregate of up to $89.2 million principal amount of the following outstanding series of its convertible notes (the "Notes"):

  • 4% Convertible Senior Subordinated Notes due 2010
  • 5.75% Convertible Senior Notes due 2011
  • 6.75% Convertible Senior Notes due 2010
  • 7.5% Convertible Senior Notes due 2011
  • 9% Convertible Senior Notes due 2012

Under the Exchange Offer, as amended, CTI will now offer to exchange shares of Common Stock and cash with a value not greater than $600 nor less than $550 (the "Exchange Consideration") for each $1,000 principal amount of Notes validly tendered and not withdrawn, with such value determined by a "Modified Dutch Auction" procedure. Originally, the minimum value had been $250 per $1,000 principal amount and the maximum value had been $300 per $1,000 principal amount. The cash portion of the Exchange Consideration will continue to be $200. Accrued and unpaid interest to, but excluding, the settlement date will continue to be exchanged for shares of Common Stock.

As a result of the increase in the portion of the Exchange Consideration consisting of shares of Common Stock, the Company has increased the maximum number of shares of Common Stock to be issued upon exchange of the Notes and to pay accrued and unpaid interest to 30.63 million shares of Common Stock.

A "Modified Dutch Auction" tender offer allows holders of the Notes to indicate the principal amount of Notes that such holders desire to tender
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA
2. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
3. Cell Therapeutics Closes Italian Facility, Reduces Headcount and Expects to Cut $14 Million in Operating Expenses
4. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
5. Orexigen(R) Therapeutics to Present at Upcoming Meetings
6. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
7. Cell Therapeutics to Exchange up to $89.2 million of Its Outstanding Convertible Notes in a Modified Dutch Auction Tender Offer
8. PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration
9. Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
10. Amicus Therapeutics to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference on May 13, 2009
11. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 Clintrax Global, Inc., a ... Raleigh, NC , recently announced ... Vice President of Administration. As ... corporate processes, including their alignment with company objectives ... worked as an HR executive, specializing in needs ...
(Date:8/20/2014)... PLANTATION, Fla. , Aug. 20, 2014 /PRNewswire/ ... it will host a conference call to provide ... 26, 2014Time:4:30 p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 ... number: 9126599 Live web cast: www.neurotropebioscience.com , under ... three hours after completion through September 2, 2014 ...
(Date:8/20/2014)... 20, 2014 The 6th Annual ... held on October 29-30 in San Francisco, CA. This ... and government researchers and clinicians focused on addressing and ... , In the twelve years since the sequencing of ... been introduced with pharmacogenetic information in the label and ...
(Date:8/20/2014)... August 20, 2014 WriteResult®, a leading ... that it has expanded its myPROpad™ ePRO tablet with ... one of the most widely used and well-respected ... health status. The EQ-5D is used during clinical trials ... measure that can be used to demonstrate Health-Related Quality ...
Breaking Biology Technology:Clintrax Global, Inc. Announces Addition to Executive Team 2Neurotrope To Host Conference Call 26th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2EQ-5D™ Assessment Now Available for iPad 2
... July 23 /PRNewswire-FirstCall/ - Roche,(SWX: ROG) and ARIUS ... have signed a definitive agreement for Roche to ... of approximately C$191 million. ARIUS is,the developer of ... and selects antibodies based on their functional,ability to ...
... ALTO, Calif., July 22 CV Therapeutics,Inc. (Nasdaq: ... quarter,financial results for 2008 after the market closes on ... call at 5:00 p.m. EDT,2:00 p.m. PDT, on the ... log on to the Company,s website at, http://www.cvt.com ...
... N.J., July 22 The Board of,Directors of BD ... declared a,quarterly dividend of 28.5 cents per common share. ... holders of record on September 9, 2008.,The indicated annual ... BD is a leading global medical technology company ...
Cached Biology Technology:Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics 2Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics 3Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics 4CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008 2
(Date:8/19/2014)... German . ... a large amount of electricity is to be produced with ... to be stored during productive periods so that these fluctuations ... from adequate for the purpose. Science and industry are therefore ... battery systems that used to be too expensive or unsophisticated ...
(Date:8/19/2014)... lemur. It,s not an African Bush Baby or even a ... downright "cool" primate from Southeast Asia. , "It,s really not ... Brown, curator-in-charge at the University of Kansas, Biodiversity Institute. "A ... body; a long tail with a furry tuft at the ... a bit like the disks on the digits of tree ...
(Date:8/19/2014)... New measurements from fish purchased at retail seafood ... to which mislabeling can expose consumers to unexpectedly ... Fishery stock "substitutions"which falsely present a fish of ... originare the most dangerous mislabeling offense, according to ... scientists. , "Accurate labeling of seafood is essential ...
Breaking Biology News(10 mins):Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3
... Canadian researcher working in the U.K. says doctors, authors ... claiming that hyperactivity as we understand it today has ... that notion wrong, it misleads patients, their parents and ... finishing up his PhD at the Centre for Medical ...
... embarrassing, but a new study suggests that it might ... interviewed more than three thousand men - all pairs ... - about the first time they had sex. Many ... from erectile dysfunction and premature ejaculation at their first ...
... for proposals, projects focus on either the development of ... and genomics. The Swiss National Science Foundation (SNSF) approved ... 47 research groups from both Swiss Federal Institutes of ... from the Universities of Basel, Lausanne, Geneva and Zurich. ...
Cached Biology News:History of hyperactivity off-base, says researcher 2Swiss Initiative in Systems Biology launches new projects 2
Wnt-1 (G-19)...
... G4-1, Affinity-Purified Polyclonal IgY Antibodies ... phosphatase subunit gene g4-1 Protein ... query: 8923600 Genbank Definition: ... likely ortholog of mouse phosphatase subunit gene ...
HSV-1 gE Envelope Protein (9H3)...
... C-terminal reactive. Cross-reacts fully with GLP-1(1-36) ... with the unamidated forms GLP-1(7-37) and ... as hGLP-2, glucagon, hGIP and VIP.,SPECIES ... identical in all mammalian species studied ...
Biology Products: